Description
About the Compound
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide engineered as a triple agonist of GLP-1, GIP and glucagon receptors, with a C20 fatty-acid chain for albumin binding. Its triple activation distinguishes it from prior incretin-agonist generations and makes it a subject of active investigation in metabolic regulation. It remains an investigational compound without regulatory approval.
Documented Activity Profile
- GLP-1 / GIP / Glucagon triagonist β triple-receptor mechanism
- Investigated for significant weight reduction in metabolic research models
- Studied for hepatic fat (NAFLD) reduction via glucagon-receptor activation
- Researched for cardiometabolic markers in metabolic-syndrome studies
Specifications
- 30mg per vial β lyophilized powder
- HPLC verified at 99%+ purity
- Third-party tested & COA verified per batch
FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT A DRUG, FOOD, OR COSMETIC. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

Reviews
There are no reviews yet.